Mucosolvan (Ambroxol Hydrochloride)

Ambroxol hydrochloride stimulates serous cells in the airway lining, increasing the secretion of thin, watery fluid. It also enhances the activity of cilia, the tiny hair‑like structures that move mucus toward the throat. The combined effect reduces mucus viscosity and promotes its clearance from the lungs.

The appropriate dose of Mucosolvan is determined by the prescribing healthcare professional based on the patient’s age, severity of the respiratory condition, and overall clinical status. Dosage may vary between acute and chronic indications, and the prescriber will provide specific instructions.

Safety data for ambroxol during pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against any possible risks before prescribing. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mucosolvan. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mucosolvan (ambroxol) differs from agents such as N‑acetylcysteine by primarily stimulating serous secretion and ciliary activity, whereas N‑acetylcysteine acts mainly by breaking disulfide bonds in mucus proteins. Both reduce mucus viscosity, but ambroxol often has a faster onset of action and a favorable tolerability profile.

Mucosolvan should be stored below 25 °C (77 °F) in its original packaging. Keep the product away from moisture, direct sunlight and extreme temperatures to maintain its stability and efficacy.

Mucosolvan is supplied as an inhalation preparation. The patient inhales the prescribed dose using a nebulizer or inhalation device as instructed by the healthcare professional, ensuring the medication reaches the lower respiratory tract where it can act on mucus.

Serious adverse events, although rare, include allergic reactions such as rash, swelling, or difficulty breathing, and bronchospasm that can cause sudden shortness of breath. If any of these symptoms occur, the medication should be stopped immediately and medical attention sought.

Mucosolvan should be avoided in individuals with known hypersensitivity to ambroxol hydrochloride or any of the formulation excipients. Patients with uncontrolled asthma or a history of severe bronchospasm should use it only under close medical supervision.